HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reckitt Records Impairment Charge For Biofreeze

Executive Summary

Reckitt recorded a £152m impairment charge for Biofreeze in 2022 after the topical pain relief brand underperformed in the first half of the year. Despite issues for Biofreeze, Reckitt's Health business as a whole had a strong showing over the 12 months, with sales jumping by 19%.

You may also be interested in...

Euro Q4 Consumer Health Earnings Preview: Sanofi, Bayer, Haleon, Reckitt

Major Europe-based consumer health players Sanofi, Bayer, Haleon and Reckitt all feature in this sales and earnings preview, which highlights what to look out for and potential talking points as these four companies report Q4 and full-year results over the coming weeks.

Haleon’s ‘#1 Doctor Recommended’ Voltaren Claim Challenged By RB Clears NAD Review With Caveat

NAD says in advertising without references to arthritis, Haleon should ensure claim Reckitt challenged “clearly and conspicuously discloses that Voltaren is approved for the treatment of arthritis pain.” Haleon supports “#1 Doctor Recommended” and “#1 Topical Pain Reliever Globally” claims.

Reckitt Claims Market Leading OTC Growth As Q1 Sales Rise Double Digits

Reckitt's OTC sales jumped 30% in Q1, helped by a strong cold & flu season, with the company enjoying market leading growth, according to interim CEO Nicandro Durante.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts